TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04113707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor lab activity
Description: fitness, gross motor, fine motor, and motor coordination activities
Study: NCT03069846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectra-Scope
Description: The Spectra-Scope consists of the light collection module and the spectral analysis module.~The light collection module is attached to the handpiece of short pulse Nd:YAG laser, and the analysis module is placed on the laser.~Each potential skin cancer site, which has previously been identified as requiring biopsy, should be assessed using five laser shots that last approximately 10 milliseconds per shot and measurement. The laser shots must be made before the scheduled biopsy.~All potentially cancerous lesions (or lesions that would usually undergo complete biopsy of the lesion or require follow up within three months) should be sampled. The Spectra-Scope will not provide a diagnosis at the time of sampling. Sites should record the spectra reported for each laser shot in the CRF.
Study: NCT02699242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulator (ORSIM) training
Description: The simulator/intervention group will undergo training on the virtual reality bronchoscopic simulator (ORSIM) for 60 minutes before the subjects perform the 2nd Fiber optic intubation
Study: NCT00361127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotonic saline infusion
Study: NCT04936724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pictorial Warning Labels
Description: Participants will be randomized to one of two conditions and will view 4 pictorial warning labels from the assigned group for an eye-tracking task.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pictorial Warning Labels
Description: Participants will be randomized to one of two conditions and will view 4 pictorial warning labels from the assigned group for an eye-tracking task.
Study: NCT00777231

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enriched Hematopoetic Stem Cell Infusion
Description: Enriched Hematopoetic Stem Cell Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enriched Hematopoetic Stem Cell Infusion
Description: Enriched Hematopoetic Stem Cell Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enriched Hematopoetic Stem Cell Infusion
Description: Enriched Hematopoetic Stem Cell Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enriched Hematopoetic Stem Cell Infusion
Description: Enriched Hematopoetic Stem Cell Infusion
Study: NCT00119730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given on days 1-3 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Given on day 1 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given on day 1 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin
Description: After two cycles if there is no disease progression, zevalin treatment will be given. Rituximab will be given followed by an imaging dose of zevalin. Two or three scans will be performed over a week to determine if it is safe to give the full treatment dose of zevalin. The treatment dose is given with the second infusion or rituximab, seven days after the first dose.
Study: NCT02800473

Intervention type: DEVICE
Group type: OTHER
Intervention: Strorz (commercial)

Intervention type: DEVICE
Group type: OTHER
Intervention: CyPaM2 (experimental)
Study: NCT05266794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha lipoic acid
Description: 20 patients who received Alpha Lipoic acid (ALA) (Thiotex fort®) 600mg once daily with their routine therapy just after the dialysis sessions for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: 23 patients who received Selenium 200µg once daily with their routine therapy just a
Study: NCT04102735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Under-the-nose facemask
Description: Patients with acute hypercapnic respiratory failure that need noninvasive ventilation and are randomized in the experimental group will receive the AF541 facemask used with the under-the-nose cushion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Over-the-nose facemask
Description: Patients with acute hypercapnic respiratory failure that need non-invasive ventilation and are randomized in the comparator group will receive the AF541 facemask used with the over-the-nose cushion.
Study: NCT05015205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Post isometric relaxation technique MET was applied in two muscle groups; Lumbar Extensors (Erector Spinae) and Hip Flexors (Iliopsoas). The muscle was positioned in position and patient was asked to apply 20% force isometrically and hold the isometric contractions for 7-10 seconds. Then the patient was asked to relax for about seconds. On exhalation, therapist takes muscle to new restriction barrier. Hold this position for 30 seconds at the end barrier as an end-stretch with 3 repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural Correction Exercises
Description: : Postural Correction Exercises was applied to one group. Exercises performed included stretching and strengthening exercises. Hip flexors and back extensors were stretched while hip extensors and abdominals were strengthened. Seated hip flexion used to stretch back extensors while lunge position used to stretch hip flexors. The abdominals were strengthened by using curl up exercises while hip extensors were strengthened by resisted contractions in prone lying.
Study: NCT00014378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herb Huanglian (Coptis chinesis)
Description: Patients will receive capsules of the powdered extract of the huanglian root, which will take by mouth 4 times a day (qid).
Study: NCT02549170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Participants will receive HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.25% albumin placebo solution with rHuPH20
Description: Participants will receive placebo solution (0.25% human albumin in Lactated Ringer's solution) and rHuPH20.
Study: NCT01265420

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injectable clostridial collagenase
Description: Injection of 0.58mg clostridial collagenase into Dupuytren's cord, up to three injections
Study: NCT02549170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGIV GAMMAGARD LIQUID/KIOVIG
Description: Participants will receive GAMMAGARD LIQUID/KIOVIG

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGIV GAMMAGARD LIQUID/KIOVIG
Description: Participants will receive GAMMAGARD LIQUID/KIOVIG

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGIV GAMUNEX®-C
Description: Participants will receive GAMUNEX®-C
Study: NCT03410446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Ketamine is a N-methyl-D-aspartate (NMDA) antagonist.
Study: NCT01161082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN727(SAR236553)
Description: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN727(SAR236553)
Description: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN727(SAR236553)
Description: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN727(SAR236553)
Description: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN727(SAR236553)
Description: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN727(SAR236553)
Description: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN727(SAR236553)
Description: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN727(SAR236553)
Description: subcutaneous
Study: NCT04447755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsules administered orally at 14 mg/m\^2 QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsules administered orally at 14 mg/m\^2 QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsules administered orally at 14 mg/m\^2 QD
Study: NCT04116450

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Glaucolight illuminated microcatheter.
Description: To study circumferential trabeculotomy for congenital glaucoma using Glaucolight illuminated microcatheter.
Study: NCT00643591

Intervention type: OTHER
Intervention: imaging (dynamic PET-CT scan)
Description: dynamic PET-CT scan
Study: NCT02990897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: clinical decision support message
Description: The intervention patient's physician is shown an estimate of the patient's 5 year risk of ESRD with a link for further information.
Study: NCT00539253

Intervention type: DRUG
Group type: OTHER
Intervention: gadobenate dimeglumine (MultiHance)
Description: The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.
Study: NCT02892565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Study: NCT03426878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified genetic counseling
Description: After participants at high risk for a hereditary cancer syndrome receive exome sequencing, they will receive modified genetic counseling to help them understand the results.
Study: NCT02892565

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Study: NCT03953261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin supplement
Description: Intervention is 2 grams of curcumin supplement per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Curcumin supplement
Description: Intervention is 2 grams of curcumin supplement per day
Study: NCT04345926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Stepped propofol concentration after 20 min of LOS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalogram recording
Description: Acquisition of EEG activity
Study: NCT00570752

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-582949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study: NCT03426878

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional genetic counseling
Description: After participants at high risk for a hereditary cancer syndrome receive exome sequencing, they will receive traditional genetic counseling to help them understand the results.
Study: NCT03310112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-week MBAT
Description: The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 4 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2-week MBAT
Description: The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 2 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.
Study: NCT01257932

Intervention type: DEVICE
Intervention: Diffuse Optical Spectroscopy Imaging
Description: Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy
Study: NCT00463788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab, cisplatin
Description: Subjects will receive an initial dose of cetuximab 400 milligram per square meter (mg/m\^2) followed by weekly doses of 250 mg/m\^2. All doses will be given by intravenous (IV) infusion.~Subjects will receive cisplatin (75 mg/m\^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Administration of the Investigational Medicinal Product (IMP) will be stopped upon the first occurrence of disease progression, unacceptable toxicity or withdrawal of consent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Subjects will receive cisplatin (75 mg/m\^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Subjects have the option of receiving cetuximab plus cisplatin at progression within the first 6 cycles, or cetuximab alone at progression after the 6 cycles.~Administration of the IMP will be stopped upon the first occurrence of disease progression (except in cisplatin arm where switch to cetuximab plus cisplatin, or cetuximab alone is possible), unacceptable toxicity or withdrawal of consent.
Study: NCT00570752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Study: NCT02534311

Intervention type: DRUG
Intervention: Tocilizumab
Description: Tocilizumab will be administered at 162 mg SC injection for 48 weeks.
Study: NCT00459745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravafen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Study: NCT01373697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Apply the gel at the site of pain or injury, massaging gently to promote penetration of 8 in 8 hours for 5 days. Leave the gel on the premises at least 4 hours before removal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Profenid
Description: Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
Study: NCT04129619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORP-101
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORP-101
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet
Study: NCT01843348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Capsules: 0.5 mg, 1 mg or 5 mg. Dosing schedule: transplant to month 2: 4-8ng/ml, month 3 to month 12 3-5 ng/ml according to standard blood levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Capsules: 0.5 mg, 1 mg or 5 mg. Dosing schedule: transplant to month 2: 4-8ng/ml, month 3 to month 12 3-5 ng/ml according to standard blood levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: Capsules: 10 mg, 25 mg, 50 mg or 100 mg. Transplantation to month 2: 75 - 125 ng/ml, month 3 to month 12: 50 - 100 ng/ml
Study: NCT02634970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg, intravitreal injection
Study: NCT02903615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel diet
Description: Novel diet to optimise glucose levels and minimise systemic inflammation: altered macronutrient composition: lower carbohydrate, Mediterranean-style, prebiotic fibre focus.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard diet
Description: Standard diabetes diet recommendations
Study: NCT04233632

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FC2 Condom
Description: FC2: FC2 is composed of a synthetic nitrile rubber latex and 170mm in length. It has a flexible inner ring as the internal retention mechanism and a circular ring as the outer retention mechanism at the open end of the condom. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is available in clear and other colors/scents. It is manufactured by Female Health Company, USA and has USFDA, World Health Organisation (WHO)/United Nations Populations Fund (UNFPA) and South African Bureau of Standards (SABS) approval

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cupid Condom
Description: Cupid is composed of a Natural rubber latex and is 155mm in length. It has a Medical grade sponge as the internal retention mechanism and an octagonal outer frame as the outer retention mechanism. It is pre-lubricated with silicone oil. It has a shelf-life of 3 years and is available in clear and red color, vanilla scented variety. It is manufactured by Cupid Ltd, India and has WHO)/UNFPA, India Drug Control Authority, Conformitè Europëenne (CE) Mark of the European Union (EU) and SABS approval

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cupid 2 Condom
Description: Cupid2 is composed of a Natural rubber latex and is 125mm in length. It has a Medical grade sponge as the internal retention mechanism and an octagonal outer frame as the outer retention mechanism. It is pre-lubricated with silicone oil. It has a shelf-life of 3 years and is available in Clear and purple color, vanilla scented variety. It is manufactured by Cupid Ltd, India and has WHO)/UNFPA, India Drug Control Authority, CE Mark of the EU and SABS approval
Study: NCT00742300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation
Description: Transplantation of CD34-selected autologous hematopoietic stem cells after high-dose chemotherapy with cyclophosphamide (200mg/kg) and rabbit-antithymocyteglobulin (90mg/kg)
Study: NCT01667796

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Study: NCT03370796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminiscence Therapy Program
Description: The Reminiscence Therapy program is composed of: (i) main strand lasting 7 weeks, with sessions twice a week (total of 14 sessions); (ii) maintenance strand, which runs for 7 weeks, once a week (total of 7 sessions). The duration for each session will be 60 minutes.
Study: NCT00885157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated types 1, 2, and 3 poliovirus, D antigens
Description: 0.1 mL, intradermal

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated types 1, 2, and 3 poliovirus, D antigens
Description: 0.5 mL, Intramuscular
Study: NCT04377815

Intervention type: OTHER
Intervention: General Public cohort
Description: No intervention is being tested
Study: NCT01647438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 6 to 8 participants who will attend 6 weekly, 90 minute group education sessions at Metropolitan Asian Family Services. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management. Participants will receive telephone support after each session and up to 12 weeks after they have completed the classes to help reinforce learning objectives.

Intervention type: OTHER
Group type: OTHER
Intervention: Print Health Education
Description: Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
Study: NCT00911521

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human papillomavirus vaccination (Gardasil)
Description: 3 doses of the human papillomavirus vaccines to be given at baseline, month 2 and month 6
Study: NCT01860612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Iris (CustomFlex)
Study: NCT01843348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric Coated Mycophenolate Sodium (EC-MPS)
Description: Tablets: 180 mg or 360 mg. Dosing: duration of study 360 mg bid and no less than 360 mg daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Description: Capsules: 250 or 500 mg. Dosing: duration of study 500 mg bid and no less than 500 mg total daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: A minimum dose of 5 mg prednisolon or equivalent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: A minimum dose of 5 mg prednisolon or equivalent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: A minimum dose of 5 mg prednisolon or equivalent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simulect
Description: Lyophilisate in vials with ampoules of sterile water for injection (5 mL), one vial containing 20 mg lyophilisate given intravenously on the day of transplantation and on day four post-transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simulect
Description: Lyophilisate in vials with ampoules of sterile water for injection (5 mL), one vial containing 20 mg lyophilisate given intravenously on the day of transplantation and on day four post-transplantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simulect
Description: Lyophilisate in vials with ampoules of sterile water for injection (5 mL), one vial containing 20 mg lyophilisate given intravenously on the day of transplantation and on day four post-transplantation.
Study: NCT00958126

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL425
Description: CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL425
Description: CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL425
Description: CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaccine diluent, thimerosal 0.01% (weight/volume).
Study: NCT01481740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine bolus
Description: 10 ml of 100mcg/ml phenylephrine and placebo infusion